Objectives: Raised vancomycin MICs have been associated with poor outcomes for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in the USA and mainland Europe. We investigated if this also applies in the UK, where EMRSA-15 (clonal complex 22) dominates.
Introduction
Vancomycin is a standard first-line treatment for methicillinresistant Staphylococcus aureus (MRSA) bacteraemia and any failure against supposedly 'susceptible' isolates has major public health and patient-care implications. It is therefore disturbing that recent years have seen growing assertions that infections due to MRSA isolates with slightly reduced susceptibility to vancomycin have increased failure rates for glycopeptide therapy.
Based on pharmacodynamic considerations, the CLSI, EUCAST and BSAC have all reduced their susceptible vancomycin breakpoints from ≤4 to ≤2 mg/L, 1 -3 but these revised values may still be too high and increased failure rates or longer clearance times have been reported for bacteraemias caused by MRSA isolates with vancomycin MICs of 1-2 mg/L compared with MICs ,1 mg/L. 4, 5 On this basis, there have been calls to further reduce the breakpoints. 6, 7 If this was to happen, the majority of UK MRSA isolates ( 94% based on the BSAC bacteraemia surveillance, http://www. bsacsurv.org) would be reclassed as non-susceptible.
However, caution is necessary in extrapolating these largely American studies of MIC versus outcome, as the patients were almost certainly infected by clones other than the EMRSA-15 (ST22-IV) variants that predominate in the UK 8 and because MICs generally were determined by CLSI broth microdilution, a method little used in the UK. A further complicating factor is that rifampicin is often coadministered with vancomycin in the UK and Burnie et al. 9 found that outcomes in EMRSA-15 bacteraemia were greatly improved if rifampicin was microbiologically active and could be coadministered.
To understand the situation in the UK, more data are requiredspecifically for EMRSA-15. To address this, we conducted a large multicentric outcome analysis of vancomycin treatment for MRSA bacteraemia from 2008 to 2010.
Methods

Case definition
Consecutive patients with MRSA bacteraemia treated with vancomycin for ≥3 days during the period October 2008 to August 2010 were eligible for inclusion. Each patient could only be included once; for patients with multiple episodes of MRSA bacteraemia, only the first episode was considered.
Hospitals
Twenty-four hospital sites were recruited across the UK. Care was taken to ensure that these were representative, in terms of geography and case mix, to the generality of UK hospitals, though inclusion was perforce restricted to those sites that had the resources and interest to participate.
Isolate and data collection
Participating sites were requested to submit MRSA isolates from all bacteraemia cases to the then Antibiotic Resistance Monitoring & Resistance Laboratory (now Antimicrobial Resistance & Healthcare Associated Infection Reference Unit) during the study period. The hospitals provided clinical information ≥28 days after cessation of vancomycin therapy; these data included patient age, sex, underlying medical condition, treatment and clinical outcome in terms of mortality and resolution of bacteraemia (i.e. cessation of clinical signs and symptoms of bacteraemia). Data on measured vancomycin trough levels were also sought.
Isolate characterization
Vancomycin MICs for the collected isolates were determined centrally in five separate replicate tests by BSAC 10 and CLSI 11 agar dilution with a p 2 dilution series. In addition, all isolates were screened for the mecA and Panton-Valentine leucocidin (PVL) genes 12 and characterized based upon a polymorphic 24 bp variable-number tandem repeat within the 3 ′ coding region of the S. aureus-specific staphylococcal protein A (spa) gene, as detailed previously. 13 The multilocus sequence type clonal complex (MLST-CC) was inferred from the spa repeat succession data by reference to Ridom SpaServer (www.spaserver.ridom.de) 14 and Monecke et al. 15 
Statistical analysis
Data were analysed for any association between the vancomycin MIC (taken as the modal value among the five replicate tests within each method) and patient outcome 28 days after the end of vancomycin therapy. Single-variable analysis was undertaken for the vancomycin MIC as measured by either the BSAC or CLSI method (with categories of 0.5-0.7 versus 1.0-1.4 and 0.5-0.7 versus 1.0 versus 1.4-2.0 mg/L, respectively) using fixed-effects logistic regression models, constructed with either resolution of bacteraemia or mortality within 28 days of vancomycin cessation as the outcome.
Mixed-effects logistic regression models were constructed with either (i) resolution of bacteraemia or (ii) mortality within 28 days of cessation of vancomycin therapy as the outcome in relation to the MIC as determined by the CLSI or BSAC method. Potentially confounding variables included in the model were patient age and sex, coadministration of rifampicin, time of onset of bacteraemia relative to hospital admission, previous hospital admission within the past 3 months, likely source of bacteraemia, underlying medical condition and spa type. Descriptions of these variables are outlined in Table 1 . Possible synergy between vancomycin and rifampicin was also investigated a priori by including coadministration of rifampicin as an effect modifier. Reporting hospital was included in each model as a source of random effect.
The association between outcome and each variable (MIC, confounding variables or rifampicin coadministration) was assessed using the likelihood ratio test (LRT). The interaction was tested for significance and, if not significant as judged by the LRTat the 5% level, was then dropped from the model. Where data for a potential confounding variable were available for ≤80% of patients, the impact of removing the variable from each model was tested by comparing the ORs and LRT P values for models including or excluding the variable. A variable with missing data was dropped from the model where there was little impact (,10% difference) on ORs and where the LRT P value was large (P. 0.2). This was done for one variable at a time in a backwards stepwise procedure, starting with the non-significant variable with the most missing data, until all such confounders had been considered, resulting in the final model.
Ethics
This study was an audit of routinely collected data, patient care was not impacted and ethics approval was not required.
Results
Case mix
Three-hundred-and-seventy-three isolates and associated case record forms were submitted to the study from the 24 sites. Of these, 145 cases were excluded for reasons as follows: patient's notes not available (72 cases), patient not treated with vancomycin for ≥3 days (55 cases), previous enrolment of the same patient (12 cases) and methicillin resistance not confirmed by agar dilution and mecA PCR negative (6 cases). The maximum and modal numbers of cases per site were 28 and 8, respectively; two sites only contributed single cases. Table 2 summarizes the characteristics of the 228 evaluable cases. The majority were male (n¼ 149, 65%) and the median age was 70.5 years. Most (n¼ 113, 49.5%) were suffering from a single chronic underlying medical condition, e.g. renal failure, diabetes mellitus or cardiovascular disease, whereas 43 (18.8%) had two or more morbidities and 39 (17.1%) and had an acute condition, e.g. trauma. No underlying medical condition was stated for 33 cases. The predominant sources of bacteraemia (n¼ 76, 33.3%) were intravenous (iv) lines and other removable devices (e.g. infected pacemakers), whereas the source of the bacteraemia was unreported in 33 (14.4%) of cases and not established in 16 (7.0%). Forty-nine percent of the bacteraemias were considered to be nosocomial, based on symptoms becoming manifest .48 h after the patient was admitted to hospital, and half of the patients (80/162) with data available had been in hospital at some point in the 3 months prior to the bacteraemia episode reviewed in the study. Two patients were identified as having had bacteraemic episodes with S. aureus during hospitalization in the preceding 3 months.
Vancomycin MIC distributions Figure 1 shows the distributions of modal vancomycin MICs for the individual isolates by the BSAC and CLSI agar dilution methods, based on five replicate determinations per isolate by each method, each with a p 2 mg/L dilution series. Over 96.4% of modal MICs by the BSAC method were either 0.7 or 1 mg/L, with just 1.75% of values at 0.5 mg/L and 1.75% at 1.4 mg/L, whereas 76.3% of modal MICs by the CLSI method fell at 1 mg/L, with 11.8% of values each side of this mode, at 0.5-0.7 and 1.4-2 mg/L. The MIC scatter for EMRSA-15 isolates alone (see Figure 1) was not materially different from that for the totality of isolates and there was little MIC variation within the series of five replicate tests per isolate by each method. Specifically, there was no variation in MIC in the replicate testing for 40% of cases when the BSAC method was used or in 45% of cases with the CLSI method and deviation from the mode for any given replicate value never exceeded one p 2 dilution.
Clonality of isolate collection
All isolates were mecA positive and PVL negative.
As is typical in the UK, the MRSA were largely clonal: 82% (n¼ 187) belonged to the EMRSA-15 (CC22) lineage, whereas 8.8% (n¼ 20) were EMRSA-16 (CC30). MRSA vancomycin treatment outcome 2643 
JAC
Multiple spa types associated with the EMRSA-15 and -16 lineages were identified. In total, there were 43 different spa types among the EMRSA-15 isolates: t032 was the most common, accounting for 108 isolates (57.8%), followed by t022 (n¼ 12; 6.4%), t020 (n¼11; 5.9%) and 4 types (t1041, t718, t492 and t379) with 3-6 representatives each; the remaining 40 belonged to 36 different spa types. Among the 20 EMRSA-16 isolates, spa type t018 was dominant (n¼ 12; 60%); the remainder belonged to t012 (n¼5), t019 (n ¼1), t253 (n¼ 1) and t1662 (n¼ 1). The 21 non-EMRSA-15 and -16 isolates belonged to six different MLST-CCs (Table 3) .
Patient outcomes
Outcome data were available for 223 of the 228 eligible cases, with data on coadministration (or not) of rifampicin for 221 of these. Fifty-three patients (24%) died within 28 days of the end of vancomycin therapy, with the MRSA bacteraemia identified as a significant contributory factor to death in 25 of these (47%). Nine other patients who died were known to be on palliative care pathways. Among patients receiving vancomycin monotherapy, 40/160 died (25%) compared with 12/61 (20%) of those receiving vancomycin and rifampicin combination therapy (P ¼ 0.4).
ORs, unadjusted for other factors, indicated patient death was at least two and a half times more likely in cases where the bacteraemia was caused by isolates with vancomycin MICs of 0.5 -0.7 mg/L by the BSAC agar method compared with those with vancomycin MICs of ≥1 mg/L (Table 4) . A similar relationship appeared to apply when MICs were determined by the CLSI methods, though it should be noted that there were few MICs of 0.5 -0.7 mg/L by this latter method (Figure 1 ). These counterintuitive associations between low MICs and increased mortality vanished once the model was adjusted for other factors (Table 4 ) and the only factor that remained strongly associated with increased mortality in the multivariable model was increasing patient age. There was no evidence of interaction between vancomycin MIC and coadministration of rifampicin in relation to patient outcome (P .0.09). Patient outcome models are adjusted for hospital (as a random effect), patient age and sex, coadministration of rifampicin, timing of bacteraemia onset relative to admission, likely source of infection and spa type (all as fixed effects). The model using MICs by the CLSI method was also adjusted for type of underlying medical condition. The model for resolution of bacteraemia was adjusted for hospital (as a random effect), patient age and sex, coadministration of rifampicin, timing of bacteraemia onset relative to admission, likely source of infection, type of underlying medical condition and spa type (all as fixed effects).
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Bacteraemia resolution
The bacteraemia remained unresolved by vancomycin therapy in 38 cases (17%). Twenty-seven of these cases received vancomycin alone and 11 in combination with rifampicin, comprising 17% (27/155) and 20% (11/56) of all cases, respectively. For a further 17 cases, it was not reported whether the bacteraemia had resolved or not. Some patients were switched to different antibiotics when they were taken off vancomycin and this was counted as a failure of vancomycin therapy, irrespective of the patient's ultimate outcome.
As in the patient mortality analysis above, unadjusted ORs indicated that non-resolution of bacteraemia was associated, counterintuitively, with low vancomycin MICs (see Table 4 ), but, again, this association was discounted once confounding factors were included in the model. Underlying medical condition remained an important factor for resolution of the bacteraemia, with vancomycin much less likely to clear the bacteraemia (P ≤ 0.01) in patients who had multiple pathologies than in patients with acute or single chronic conditions. Including hospital as a random effect in the bacteraemia resolution model improved the fit, whereas this was not the case in the patient mortality analysis. Once again, there was no evidence of interaction between the vancomycin MIC and coadministration of rifampicin in relation to bacteraemia outcome (P .0.09). Unlike in the model for patient mortality, patient age was not a significant factor for resolution of the bacteraemia by vancomycin therapy (P≥ 0.1).
Vancomycin trough levels
Vancomycin serum trough levels were recorded where available. One-hundred-and-sixty-seven cases (73%) had at least one trough level recorded, but only 65 (28%) had trough levels recorded for ≥50% of treatment days and just 25 (11%) had results for ≥75% of treatment days. The median trough level was 13.3 mg/L and the mean was 13.9 mg/L. These values increased to ≥15 mg/L when only those cases with results on ≥50% treatment days were considered, implying that better levels were obtained for patients who were monitored more closely. The minimum recorded trough level was 0.9 mg/L, whereas the highest was 43.1 mg/L. Low trough levels were not correlated with poor patient outcomes or bacteraemia resolution (P.0.8).
Discussion
The assertion that 'high' vancomycin MICs within the susceptible range are associated with worse outcomes in MRSA bacteraemia than 'low' MICs has generated much discussion. This claim was initially made by Sakoulas et al., 4 who found poorer in vitro killing of vancomycin-susceptible MRSA with 'high' MICs (≥1 mg/L) compared with those with lower MICs and who linked this reduced cidality with increased rates of treatment failure in MRSA bacteraemia. Where there was a ,4.71 log 10 cfu reduction in vitro over 72 h, all patients failed, whereas when there was a 4.71 log 10 to 6.26 log 10 cfu reduction, the failure rate fell to 76.9%, with a further fall in the failure rate, to 50%, when a .6.27 log 10 cfu reduction was achieved. Holland and Fowler 16 recently summarized 13 studies published from 2004 to 2011 that support the view that MRSA isolates with higher vancomycin MICs were associated with significantly more treatment failures than those with lower MICs. Eleven of these studies-7 of them from the USA-included MRSA bacteraemia cases; they variously used MIC determination by broth microdilution, Vitek and/or Etest, though not by agar dilution, as here. Eight of these studies reported significant differences in the outcome between MRSA with vancomycin MICs of ≤1 and ≥2 mg/L, 17 -24 whereas the remaining three studies observed significant differences in the outcome between MICs of ≤0.5 and ≥1 mg/L. 4, 25, 26 Several of the studies that utilized Etests reported their MICs on a half-log scale 20 -22,27 and an additional study, not included by Holland and Fowler, 16 found the finer scale offered by the Etest method was of benefit when predicting outcome, although they did not address the issue of Etest accuracy. 28 In the present study, we sought to improve the MIC precision both by performing multiple determinations, by using both CLSI and BSAC methods and by use of a p 2 dilution series, but found no association with 'high susceptible' vancomycin MICs and worse outcomes in MRSA bacteraemia.
Our findings are in keeping with studies in the USA by Crompton et al., 29 Honda et al. 30 and Han et al., 31 who all concluded that there was no significant difference between clinical failure rates for infections caused by MRSAwith vancomycin MICs of ≤1 versus ≥2 mg/L; however, Han et al. 31 did observe worst outcomes in patients with methicillin-susceptible S. aureus bacteraemia when the MIC was .1 mg/L. In the UK, Price et al. 27 compared outcomes for S. aureus bacteraemias where the vancomycin MIC was ,1 versus .1.5 mg/L and found that mortality was greater among the patients with infections caused by isolates in the lower MIC group. This counterintuitive pattern, which was for a UK hospital dominated by EMRSA-15/-16, was also seen in the current data until the model was adjusted for confounding factors. A similar effect was seen in a study by a Spanish group, although they further noted that shock was associated with the infections due to isolates with low vancomycin MIC and that when this was considered as a negative confounder, then a positive correlation between outcome and high MIC emerged. 21 A recent study of 139 MRSA bacteraemias treated with vancomycin in New Mexico, USA, concluded that the outcome was not related to the MIC, but, rather, to the underlying source of the bacteraemia; 32 in contrast, the present study failed to establish a link between the outcome and the source of bacteraemia (P ≥ 0.08).
Strikingly, a large multicentre US study, with 532 patients suffering from S. aureus bacteraemia, showed that vancomycin MICs of .1.5 mg/L were associated with increased mortality, regardless of whether the patient had received vancomycin treatment. 33 This finding implies that the vancomycin MIC may be acting as a confounder in those studies where an association between MIC and outcome is found, segregating cases according to their causative clones, with any outcome differential reflecting the relative virulence of the clones and not the MIC per se. Walraven et al.
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(whose main conclusion, above, was that outcome reflected the source of bacteraemia) considered the virulence factors, accessory gene regulator function and PVL production in their model, but found none of them was significant. Nevertheless, this was not a comprehensive consideration of the impact of virulence factors on outcome. More generally, the impact of clonality on outcomes in the published literature is difficult to judge, as typing of isolates was often not included and, where it was included, numbers of MRSA vancomycin treatment outcome 2645 JAC isolates per clone were small. A key feature of the present studyand of the MRSA situation in the UK-is the dominance of a single clone, EMRSA-15, which accounted for 82% (187/228) of isolates from enrollable patients. This homogeneity leaves us sanguine that our findings were not skewed by a population of diverse clones. Moreover, clonal type was not found to be a significant factor (P .0.2) for outcome.
A striking observation is that the addition of rifampicin to therapy did not improve outcomes. This finding is in contrast to the results of Burnie et al., 9 for bacteraemia due to EMRSA-15, who found that mortality was least (4%) in patients with rifampicin-susceptible isolates treated with vancomycin and rifampicin, rising to 38% in patients who were treated with both antibiotics but whose organism became resistant to rifampicin during therapy and reaching 78% among patients who had rifampicinresistant isolates or in whom rifampicin was contraindicated. All of the cases in the current study where rifampicin was coadministered were due to rifampicin-susceptible MRSA.
Vancomycin trough level data were poorly completed, with data available for few of the treatment days for most patients. However, the data we do have indicate a mean vancomycin trough level of 13.9 mg/L. This is above the minimum 10 mg/L level, but below the 15-20 mg/L level recommended for infections caused by 'less sensitive strains of MRSA' in the British National Formulary. 34 Nevertheless, even if the upper boundary of this range is attained, it only achieves an area under the curve/MIC ratio at the recommended target of ≥400 for S. aureus with MICs ≤1 mg/L and is unachievable with conventional dosing (i.e. 1 -1.5 g every 12 h) if the vancomycin MIC is ≥2 mg/L in patients with normal renal function (i.e. creatinine clearance of 70 -100 mL/min). 35 Due to the poor completion rate, the trough level data were not included in the statistical analysis; however, low trough levels were not generally associated with worse outcomes.
Conclusions
Subtle vancomycin MIC differences, found by the BSAC or CLSI method, did not correlate with worse bacteraemia outcomes for vancomycin monotherapy or for vancomycin/rifampicin co-therapy, even when a high-resolution p 2 dilution series was used to determine the MICs. This finding is in contrast to the conclusions of a number of previous studies, but agrees with an increasing body of counter evidence indicating that 'subsusceptible' vancomycin MICs are not predictors of poor therapy outcome. Regardless of the true MIC-outcome relationship, detecting such small effects seems unlikely to be reliable in routine laboratories.
